busulfan has been researched along with Disease Exacerbation in 56 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 9.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| "We evaluated the toxicity and outcome of a conditioning regimen comprising intravenous (iv) busulfan (BU) and melphalan (MEL) in 55 patients (median age, 61 years; range, 34-71) with multiple myeloma (MM) undergoing autologous stem-cell transplantation (ASCT)." | 9.14 | Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. ( Alegre, A; Blanes, M; de la Rubia, J; González, JD; Lahuerta, JJ; Ribas, P; Sanz, MA; Solano, C, 2009) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 9.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma." | 9.12 | Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007) |
| "Gemcitabine plus treosulfan (GeT) is under investigation in metastatic uveal melanoma." | 9.11 | Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. ( Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E, 2005) |
| "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients." | 9.10 | Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. ( Baumgart, J; Deutschmann, A; Hauschild, A; Mohr, P; Neuber, K; Pföhler, C; Pichlmeier, U; Reinhold, U, 2003) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 9.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| "We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients (age, ≥60 years) with pretreated relapsed American Joint Committee on Cancer stage IV cutaneous malignant melanoma." | 7.77 | Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2011) |
| "The present clinical trial was undertaken to investigate the toxicity and antimyeloma activity of busulfan (BU) and cyclophosphamide (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive patients with multiple myeloma (MM)." | 7.70 | High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. ( Bandini, G; Belardinelli, A; Benni, M; Bonini, A; Cavo, M; Gozzetti, A; Lemoli, RM; Motta, MR; Rizzi, S; Ronconi, S; Rosti, G; Tura, S; Zamagni, E, 1998) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 5.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| "We evaluated the toxicity and outcome of a conditioning regimen comprising intravenous (iv) busulfan (BU) and melphalan (MEL) in 55 patients (median age, 61 years; range, 34-71) with multiple myeloma (MM) undergoing autologous stem-cell transplantation (ASCT)." | 5.14 | Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. ( Alegre, A; Blanes, M; de la Rubia, J; González, JD; Lahuerta, JJ; Ribas, P; Sanz, MA; Solano, C, 2009) |
| "We report long-term results after a median follow-up of 105 months in 18 patients with multiple myeloma who received an intensified myeloablative conditioning regimen regimen consisting of modified total body irradiation, busulfan, cyclophosphamide, and antithymocyte globulin, followed by allogeneic stem cell transplantation (SCT)." | 5.14 | Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. ( Derigs, G; Einsele, H; Kröger, N; Krüll, A; Wandt, H; Zander, A, 2010) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 5.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma." | 5.12 | Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007) |
| "Gemcitabine plus treosulfan (GeT) is under investigation in metastatic uveal melanoma." | 5.11 | Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. ( Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E, 2005) |
| "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients." | 5.10 | Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. ( Baumgart, J; Deutschmann, A; Hauschild, A; Mohr, P; Neuber, K; Pföhler, C; Pichlmeier, U; Reinhold, U, 2003) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 5.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| "We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients (age, ≥60 years) with pretreated relapsed American Joint Committee on Cancer stage IV cutaneous malignant melanoma." | 3.77 | Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2011) |
| " All the patients were conditioned with cyclophosphamide and busulfan, and treated with cyclosporin (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis." | 3.77 | Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. ( Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y, 2011) |
| " In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)." | 3.72 | Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003) |
| "The present clinical trial was undertaken to investigate the toxicity and antimyeloma activity of busulfan (BU) and cyclophosphamide (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive patients with multiple myeloma (MM)." | 3.70 | High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. ( Bandini, G; Belardinelli, A; Benni, M; Bonini, A; Cavo, M; Gozzetti, A; Lemoli, RM; Motta, MR; Rizzi, S; Ronconi, S; Rosti, G; Tura, S; Zamagni, E, 1998) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "This study indicates that in myelofibrosis, NMA regimens result in high engraftment failure rates." | 1.42 | Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. ( Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S, 2015) |
| "Controversial issues in chronic idiopathic myelofibrosis (IMP) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis." | 1.32 | Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. ( Diehl, V; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J, 2003) |
| "The patient who had trisomy 8 at the time of diagnosis underwent myeloid blastic transformation in 35 months." | 1.31 | Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. ( Hirose, Y; Masaki, Y; Sugai, S, 2002) |
| "Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases." | 1.30 | Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. ( Alimoghadam, K; Ghahremani, G; Ghavamzadeh, A; Jahani, M; Khodabandeh, A; Nasseri, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (17.86) | 18.2507 |
| 2000's | 24 (42.86) | 29.6817 |
| 2010's | 21 (37.50) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Shimoni, A | 1 |
| Robin, M | 1 |
| Iacobelli, S | 1 |
| Beelen, D | 1 |
| Mufti, GJ | 1 |
| Ciceri, F | 1 |
| Bethge, W | 1 |
| Volin, L | 1 |
| Blaise, D | 4 |
| Ganser, A | 2 |
| Luft, T | 1 |
| Chevallier, P | 1 |
| Schwerdtfeger, R | 1 |
| Koster, L | 1 |
| de Witte, T | 1 |
| Kröger, N | 3 |
| Nagler, A | 1 |
| Yakoub-Agha, I | 1 |
| Yu, ZP | 1 |
| Ding, JH | 1 |
| Sun, AN | 1 |
| Ge, Z | 1 |
| Chen, BA | 1 |
| Wu, DP | 1 |
| Tefferi, A | 3 |
| Barbui, T | 1 |
| Hamidieh, AA | 2 |
| Eslami Shahre Babaki, A | 1 |
| Rostami, T | 1 |
| Kasaeian, A | 1 |
| Koochakzadeh, L | 1 |
| Sharifi Aliabadi, L | 1 |
| Behfar, M | 2 |
| Ghavamzadeh, A | 3 |
| Saillard, C | 1 |
| Crocchiolo, R | 1 |
| Furst, S | 1 |
| El-Cheikh, J | 1 |
| Castagna, L | 1 |
| Signori, A | 1 |
| Oudin, C | 1 |
| Faucher, C | 3 |
| Lemarie, C | 1 |
| Chabannon, C | 3 |
| Granata, A | 1 |
| Koenigsmann, M | 1 |
| Casper, J | 1 |
| Kahl, C | 1 |
| Basara, N | 1 |
| Sayer, HG | 1 |
| Behre, G | 1 |
| Theurich, S | 1 |
| Christopeit, M | 1 |
| Mohren, M | 1 |
| Reichle, A | 1 |
| Metzner, B | 1 |
| Stadler, M | 1 |
| Uharek, L | 1 |
| Balleisen, L | 1 |
| Hinke, A | 1 |
| Hinke, R | 1 |
| Niederwieser, D | 1 |
| Choi, I | 1 |
| Yoon, SR | 1 |
| Park, SY | 1 |
| Kim, H | 1 |
| Jung, SJ | 1 |
| Jang, YJ | 1 |
| Kang, M | 1 |
| Yeom, YI | 1 |
| Lee, JL | 1 |
| Kim, DY | 1 |
| Lee, YS | 1 |
| Kang, YA | 1 |
| Jeon, M | 1 |
| Seol, M | 1 |
| Lee, JH | 2 |
| Kim, HJ | 1 |
| Yun, SC | 1 |
| Lee, KH | 1 |
| Alvarez-Larrán, A | 1 |
| Martínez-Avilés, L | 1 |
| Hernández-Boluda, JC | 1 |
| Ferrer-Marín, F | 1 |
| Antelo, ML | 1 |
| Burgaleta, C | 1 |
| Mata, MI | 1 |
| Xicoy, B | 1 |
| Martínez-Trillos, A | 1 |
| Gómez-Casares, MT | 1 |
| Durán, MA | 1 |
| Marcote, B | 1 |
| Ancochea, A | 1 |
| Senín, A | 1 |
| Angona, A | 1 |
| Gómez, M | 1 |
| Vicente, V | 1 |
| Cervantes, F | 1 |
| Bellosillo, B | 1 |
| Besses, C | 1 |
| Dehghani, SS | 1 |
| Hosseini, AS | 1 |
| Jalali, A | 1 |
| Slot, S | 1 |
| Smits, K | 1 |
| van de Donk, NW | 1 |
| Witte, BI | 1 |
| Raymakers, R | 1 |
| Janssen, JJ | 1 |
| Broers, AE | 1 |
| Te Boekhorst, PA | 1 |
| Zweegman, S | 1 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 1 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Atkins, HL | 1 |
| Bowman, M | 1 |
| Allan, D | 1 |
| Anstee, G | 1 |
| Arnold, DL | 1 |
| Bar-Or, A | 1 |
| Bence-Bruckler, I | 1 |
| Birch, P | 1 |
| Bredeson, C | 1 |
| Chen, J | 1 |
| Fergusson, D | 1 |
| Halpenny, M | 1 |
| Hamelin, L | 1 |
| Huebsch, L | 1 |
| Hutton, B | 1 |
| Laneuville, P | 1 |
| Lapierre, Y | 1 |
| Lee, H | 1 |
| Martin, L | 1 |
| McDiarmid, S | 1 |
| O'Connor, P | 1 |
| Ramsay, T | 1 |
| Sabloff, M | 1 |
| Walker, L | 1 |
| Freedman, MS | 1 |
| Yang, T | 1 |
| Lin, Q | 1 |
| Ren, J | 1 |
| Chen, P | 1 |
| Yuan, X | 1 |
| Luo, X | 1 |
| Liu, T | 1 |
| Zheng, J | 1 |
| Zheng, Z | 1 |
| Zheng, X | 1 |
| Chen, X | 1 |
| Zhang, L | 1 |
| Zheng, H | 1 |
| Chen, Z | 2 |
| Hua, X | 1 |
| Le, S | 1 |
| Li, J | 1 |
| Hu, J | 1 |
| Escalón, MP | 1 |
| Stefanovic, A | 1 |
| Venkatraman, A | 1 |
| Pereira, D | 1 |
| Santos, ES | 1 |
| Goodman, M | 1 |
| Byrnes, JJ | 1 |
| Fernandez, HF | 1 |
| Blanes, M | 1 |
| de la Rubia, J | 1 |
| Lahuerta, JJ | 1 |
| González, JD | 1 |
| Ribas, P | 1 |
| Solano, C | 1 |
| Alegre, A | 1 |
| Sanz, MA | 1 |
| Atkins, H | 1 |
| Freedman, M | 1 |
| Atzpodien, J | 2 |
| Terfloth, K | 2 |
| Fluck, M | 2 |
| Reitz, M | 2 |
| Einsele, H | 1 |
| Derigs, G | 1 |
| Wandt, H | 1 |
| Krüll, A | 1 |
| Zander, A | 1 |
| Kahn, S | 1 |
| Flowers, C | 1 |
| Xu, Z | 1 |
| Esiashvili, N | 1 |
| Duchartre, Y | 1 |
| Petit, N | 1 |
| Moya, C | 1 |
| Lalanne, M | 1 |
| Dubus, P | 1 |
| Verneuil, Hd | 1 |
| Moreau-Gaudry, F | 1 |
| Richard, E | 1 |
| Fernández de Larrea, C | 1 |
| Tovar, N | 1 |
| Rozman, M | 1 |
| Rosiñol, L | 1 |
| Aróstegui, JI | 1 |
| Cibeira, MT | 1 |
| Rovira, M | 1 |
| Yagüe, J | 1 |
| Bladé, J | 1 |
| Luo, Y | 1 |
| Zhao, Y | 1 |
| Tan, Y | 1 |
| Shi, J | 1 |
| Han, X | 1 |
| Zheng, Y | 1 |
| Li, L | 1 |
| He, J | 1 |
| Xie, W | 1 |
| Ye, X | 1 |
| Cai, Z | 1 |
| Lin, M | 1 |
| Huang, H | 1 |
| Andion, M | 1 |
| Molina, B | 1 |
| Gonzalez-Vicent, M | 1 |
| Alonso, L | 1 |
| Hernandez, C | 1 |
| Lassaletta, A | 1 |
| Lopez-Ibor, B | 1 |
| Villa, M | 1 |
| Diaz, MA | 1 |
| Zain, J | 1 |
| Palmer, JM | 1 |
| Delioukina, M | 1 |
| Thomas, S | 1 |
| Tsai, NC | 1 |
| Nademanee, A | 1 |
| Popplewell, L | 1 |
| Gaal, K | 1 |
| Senitzer, D | 1 |
| Kogut, N | 1 |
| O'Donnell, M | 1 |
| Forman, SJ | 1 |
| Buhr, T | 1 |
| Büsche, G | 1 |
| Choritz, H | 1 |
| Länger, F | 1 |
| Kreipe, H | 1 |
| Neuber, K | 3 |
| Reinhold, U | 2 |
| Deutschmann, A | 1 |
| Pföhler, C | 2 |
| Mohr, P | 1 |
| Pichlmeier, U | 1 |
| Baumgart, J | 2 |
| Hauschild, A | 1 |
| Thall, PF | 1 |
| Wathen, JK | 1 |
| Bekele, BN | 1 |
| Champlin, RE | 1 |
| Baker, LH | 1 |
| Benjamin, RS | 1 |
| Mohty, M | 2 |
| Bay, JO | 2 |
| Choufi, B | 2 |
| Bilger, K | 2 |
| Tournilhac, O | 1 |
| Vey, N | 1 |
| Stoppa, AM | 1 |
| Coso, D | 1 |
| Viens, P | 2 |
| Maraninchi, D | 2 |
| Cree, IA | 1 |
| Ugurel, S | 1 |
| Kuwert, C | 1 |
| Haass, N | 1 |
| Hengge, U | 1 |
| Corrie, PG | 1 |
| Zutt, M | 1 |
| Tilgen, W | 1 |
| Thiele, J | 2 |
| Kvasnicka, HM | 2 |
| Schmitt-Graeff, A | 2 |
| Diehl, V | 2 |
| Spieth, K | 1 |
| Kaufmann, R | 1 |
| Gille, J | 1 |
| Michallet, M | 2 |
| Boiron, JM | 1 |
| Cahn, JY | 2 |
| Gratecos, N | 1 |
| Sotto, JJ | 1 |
| François, S | 1 |
| Fleury, J | 1 |
| Gravis, G | 1 |
| Viret, F | 1 |
| Braud, AC | 1 |
| Bardou, VJ | 1 |
| Claviez, A | 1 |
| Klingebiel, T | 1 |
| Beyer, J | 1 |
| Nürnberger, W | 1 |
| Ehninger, G | 1 |
| Suttorp, M | 1 |
| Dreger, P | 1 |
| Dörffel, W | 1 |
| Schmitz, N | 1 |
| Schmittel, A | 1 |
| Scheulen, ME | 1 |
| Bechrakis, NE | 1 |
| Strumberg, D | 1 |
| Bornfeld, N | 1 |
| Foerster, MH | 1 |
| Thiel, E | 1 |
| Keilholz, U | 1 |
| Deeg, HJ | 1 |
| Storer, BE | 1 |
| Boeckh, M | 1 |
| Martin, PJ | 1 |
| McCune, JS | 1 |
| Myerson, D | 1 |
| Heimfeld, S | 1 |
| Flowers, ME | 1 |
| Anasetti, C | 1 |
| Doney, KC | 1 |
| Hansen, JA | 1 |
| Kiem, HP | 1 |
| Nash, RA | 1 |
| O'Donnell, PV | 1 |
| Radich, JP | 1 |
| Sandmaier, BM | 1 |
| Scott, BL | 1 |
| Sorror, ML | 1 |
| Warren, EH | 1 |
| Witherspoon, RP | 1 |
| Woolfrey, A | 1 |
| Appelbaum, FR | 1 |
| Storb, R | 1 |
| McTiernan, A | 1 |
| Driver, D | 1 |
| Michelagnoli, MP | 1 |
| Kilby, AM | 1 |
| Whelan, JS | 1 |
| Ridola, V | 1 |
| Grill, J | 1 |
| Doz, F | 2 |
| Gentet, JC | 2 |
| Frappaz, D | 1 |
| Raquin, MA | 1 |
| Habrand, JL | 1 |
| Sainte-Rose, C | 1 |
| Valteau-Couanet, D | 1 |
| Kalifa, C | 2 |
| Kiyoi, H | 1 |
| Fukutani, H | 1 |
| Yamauchi, T | 1 |
| Kubo, K | 1 |
| Ohno, R | 1 |
| Yamamori, S | 1 |
| Naoe, T | 1 |
| Grande, M | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Sutton, L | 1 |
| Chastang, C | 1 |
| Ribaud, P | 1 |
| Jouet, JP | 1 |
| Kuentz, M | 1 |
| Attal, M | 1 |
| Reiffers, J | 1 |
| Tigaud, JM | 1 |
| Rio, B | 1 |
| Dauriac, C | 1 |
| Legros, M | 1 |
| Dreyfus, F | 1 |
| Lioure, B | 1 |
| Troussard, X | 1 |
| Milpied, N | 1 |
| Witz, F | 1 |
| Oriol, P | 1 |
| Gluckman, E | 1 |
| Ifrah, N | 1 |
| Pico, JL | 1 |
| Vilmer, E | 1 |
| Leblond, V | 1 |
| Fernández, MC | 1 |
| Gardelegui, I | 1 |
| Capote, FJ | 1 |
| Gil, JL | 1 |
| Muñoz, JA | 1 |
| Cavo, M | 1 |
| Bandini, G | 1 |
| Benni, M | 1 |
| Gozzetti, A | 1 |
| Ronconi, S | 1 |
| Rosti, G | 1 |
| Zamagni, E | 1 |
| Lemoli, RM | 2 |
| Bonini, A | 1 |
| Belardinelli, A | 1 |
| Motta, MR | 2 |
| Rizzi, S | 2 |
| Tura, S | 2 |
| Singer, IO | 1 |
| Franklin, IM | 1 |
| Clark, RE | 1 |
| Chalmers, EA | 1 |
| Kelsey, SM | 1 |
| Newland, AC | 1 |
| Sproul, AM | 1 |
| Crotty, G | 1 |
| McCann, SR | 1 |
| Goldstone, AH | 1 |
| McBride, N | 1 |
| Hepplestone, A | 1 |
| Watson, W | 1 |
| Sharp, RA | 1 |
| Tansey, PJ | 1 |
| Visani, G | 1 |
| Leopardi, G | 1 |
| Testoni, N | 1 |
| Curti, A | 1 |
| Alimoghadam, K | 1 |
| Nasseri, P | 1 |
| Jahani, M | 1 |
| Khodabandeh, A | 1 |
| Ghahremani, G | 1 |
| Bouffet, E | 1 |
| Raquin, M | 1 |
| Rodary, C | 1 |
| Demeocq, F | 1 |
| Chastagner, P | 1 |
| Lutz, P | 1 |
| Hartmann, O | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Gooley, T | 1 |
| Sanders, J | 1 |
| Bundschuh, S | 1 |
| Biermann, T | 1 |
| Roessler, G | 1 |
| Wasmus, M | 1 |
| Zankovich, R | 1 |
| Schaefer, HE | 1 |
| Openshaw, H | 1 |
| Lund, BT | 1 |
| Kashyap, A | 1 |
| Atkinson, R | 1 |
| Sniecinski, I | 1 |
| Weiner, LP | 1 |
| Forman, S | 1 |
| Hirose, Y | 1 |
| Masaki, Y | 1 |
| Sugai, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| Targeting Multiple Sclerosis as an Autoimmune Disease With Intensive Immunoablative Therapy and Immunological Reconstitution: A Potential Curative Therapy for Patients With a Predicted Poor Prognosis[NCT01099930] | Phase 2 | 24 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden - a Register-based Retrospective Observational Study[NCT05029206] | 174 participants (Actual) | Observational | 2021-05-05 | Completed | |||
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for busulfan and Disease Exacerbation
| Article | Year |
|---|---|
Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
Topics: Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio | 2008 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
17 trials available for busulfan and Disease Exacerbation
| Article | Year |
|---|---|
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft | 2017 |
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft v | 2014 |
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres | 2014 |
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease Progression; Female; He | 2016 |
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease Progression; Female; He | 2016 |
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease Progression; Female; He | 2016 |
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease Progression; Female; He | 2016 |
Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial.
Topics: Adult; Aged; Busulfan; Cell Movement; Cell Separation; Disease Progression; Female; Hematopoietic St | 2009 |
Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease Progression; Disease-Free Survival; | 2010 |
Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; B | 2011 |
Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; B | 2003 |
Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Disease Progression; Fe | 2003 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2003 |
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Cell Division; Cell Survival; C | 2003 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 2005 |
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cause of Death; Child; Chron | 2006 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan | 2007 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Fo | 1998 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
37 other studies available for busulfan and Disease Exacerbation
| Article | Year |
|---|---|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow | 2021 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens.
Topics: Adolescent; Age Factors; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease Progression; D | 2019 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2014 |
Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
Topics: Bone Marrow Cells; Busulfan; Child, Preschool; Chimerism; Combined Modality Therapy; Cyclophosphamid | 2015 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Com | 2015 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; | 2016 |
Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease Pro | 2009 |
Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Diagnosis, Differential; Disease Progres | 2009 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; C | 2011 |
Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.
Topics: Animals; Animals, Newborn; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Disease Pr | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine | 2011 |
High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 2011 |
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosp | 2011 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Tr | 2003 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi | 2003 |
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Topics: Biopsy; Bone Marrow; Busulfan; Disease Progression; Follow-Up Studies; Humans; Hydroxyurea; Interfer | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; | 2004 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Dis | 2004 |
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfa | 2006 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
Continuing immunoglobulin heavy chain gene rearrangements in chronic myeloid leukemia with recurrent B-lymphoid blast crises after bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Base Sequence; Blast Crisis; B | 1995 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisi | 1996 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.
Topics: Adult; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Bone Marrow Transplantation; B | 1996 |
[Acute myeloid leukemia developing in the course of essential thrombocythemia].
Topics: Alkylating Agents; Busulfan; Cerebral Hemorrhage; Disease Progression; Fatal Outcome; Gingival Hemor | 1996 |
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod | 1999 |
Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cycloph | 1999 |
Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biops | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.
Topics: Adult; Autoantibodies; Autoantigens; Autoimmune Diseases; Brain; Busulfan; Cells, Cultured; Combined | 2000 |
Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Chromosomes, | 2002 |